The groundbreaking success of Sildenafil undeniably transformed the medication landscape, but betting in companies strongly reliant on generic versions presents a complex picture. Although early returns were substantial, the end of patents and the rise of discounted alternatives have weakened sales. Therefore, a thorough assessment of present reven